Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 13, 2015 01:30 ET | Source: Compagnie Financière Tradition

Compagnie Financière Tradition: Revenue of CHF 837.5m; better trend than the IDB sector

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Press ReleaseLausanne, 13 March 2015 ...
March 13, 2015 01:30 ET | Source: Compagnie Financière Tradition

Compagnie Financière Tradition : Chiffre d'affaires CHF 837,5m ; Evolution meilleure que la tendance du secteur IDB

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Communiqué de presse ...
March 13, 2015 01:30 ET | Source: Compagnie Financière Tradition

Compagnie Financière Tradition : Revenue of CHF 837.5m; better trend than the IDB sector

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Press...
March 09, 2015 08:00 ET | Source: Rodinia Lithium Inc.

Rodinia Lithium Raises US$400,000 With Sale of Certain Non-Core Assets

TORONTO, ONTARIO--(Marketwired - March 9, 2015) - Rodinia Lithium Inc. ("Rodinia" or the "Company") (TSX VENTURE:RM), has entered into a definitive sale agreement with a private Argentine...
March 06, 2015 17:02 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea gibt bekannt, dass die U.S. FDA Isavuconazol die Marktzulassung zur Behandlung invasiver Aspergillose und invasiver Mucormykose erteilt hat

Basel, 6. März 2015 - Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde Food and Drug Administration (FDA) Isavuconazol für die Behandlung von...
March 06, 2015 17:02 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea reports U.S. FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis

Basel, Switzerland, March 6, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) approved Astellas' New Drug Application (NDA) for the...
March 02, 2015 09:39 ET | Source: Levon Resources Ltd.

Levon Responds to Recent Trading Activity

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 2, 2015) - Levon Resources Ltd. ("Levon" or the "Company") (TSX:LVN)(OTCQX:LVNVF)(BERLIN:LO9)(FRANKFURT:LO9) is issuing this press...
February 17, 2015 01:19 ET | Source: Basilea Pharmaceutica Ltd.

Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera(R) in Europe

Antifungal isavuconazole U.S. NDA and European MAA submissions under regulatory review - decisions expected in Q1 2015 in the U.S. and Q4 2015 in the EU First commercial launch of...
February 17, 2015 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera® in Europe

Antifungal isavuconazole U.S. NDA and European MAA submissions under regulatory review - decisions expected in Q1 2015 in the U.S. and Q4 2015 in the EU First commercial launch of antibiotic...
February 17, 2015 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea mit soliden Ergebnissen für das Geschäftsjahr 2014 - Grundlage für Vermarktung von Zevtera® in Europa gelegt

Zulassungsanträge für Antimykotikum Isavuconazol in den USA und in Europa in Prüfung - Entscheidungen in 1Q 2015 in den USA und 4Q 2015 in Europa erwartet Erste Markteinführung des Antibiotikums...